Vistagen Therapeutics, Inc. — Form 10-Q Summary
Reporting period: First quarter of fiscal 2023, the three months ended June 30, 2022. The filing was signed August 11, 2022. Vistagen is a clinical-stage biopharmaceutical company with no approved products or recurring product-sales revenue.
Financial performance and position
| Metric | Q1 FY2023 | Q1 FY2022 |
|---|---|---|
| Revenue | $0.31 million | $0.35 million |
| Research and development expense | $15.29 million | $5.46 million |
| General and administrative expense | $4.79 million | $2.64 million |
| Operating loss | $19.77 million | $7.75 million |
| Net loss | $19.78 million | $7.74 million |
| Net loss per common share, basic and diluted | $0.10 | $0.04 |
| Cash used in operating activities | $15.97 million | $6.17 million |
- Revenue was sublicense revenue under the AffaMed agreement. No product-sales revenue was reported. Given the company’s minimal revenue and research-stage operations, a conventional gross margin is not presented.
- Cash and cash equivalents were $51.99 million at June 30, down from $68.14 million at March 31, 2022. Total assets were $58.73 million; current assets were $54.99 million and current liabilities were $8.93 million.
- Total liabilities were $12.67 million. These included a $1.04 million insurance-premium financing note, operating lease obligations of $2.93 million, and deferred revenue of $2.49 million. The note bears 3.88% interest and is payable through April 2023.
- Accumulated deficit was $287.38 million. Shares issued were 206.85 million at quarter-end; 206.84 million were reported outstanding as of August 10, 2022.
Changes versus the prior-year quarter
- Net loss increased to $19.78 million from $7.74 million, while revenue decreased by $44,000.
- R&D expense rose $9.83 million, primarily reflecting PH94B Phase 3 and other clinical work, PH94B and PH10 nonclinical development, and outsourced manufacturing. Management expected R&D expense to decline in subsequent periods following changes to the PH94B program.
- G&A expense rose $2.15 million. Approximately $1.2 million of the increase related to pre-commercialization research and analysis initiated in anticipation of PALISADE-1 results; management did not expect those expenditures to recur at a similar near-term level.
- Operating cash use increased by $9.80 million year over year. The company ended the quarter with $51.99 million in cash, compared with $97.78 million at June 30, 2021.
Programs, outlook and risks
- PH94B: After quarter-end, on July 22, 2022, the company announced that the PALISADE-1 Phase 3 study did not meet its primary efficacy endpoint for acute anxiety treatment in adults with social anxiety disorder. The study’s safety profile was described as favorable and consistent with prior studies.
- At the report date, enrollment in the replicate PALISADE-2 trial was paused pending an independent third-party interim analysis. Recruitment and enrollment in the PALISADE open-label safety study were ended in August. Management cited preliminary open-label data suggesting possible improvement over repeated as-needed use, but these data were preliminary and not published.
- Management planned to discuss PH94B’s further development with the FDA after reviewing the PALISADE-2 interim analysis. It also said it was deferring or cancelling certain PH94B development and pre-commercialization activities, which it expected to reduce near-term cash needs.
- Other candidates: The exploratory Phase 2A study of PH94B for adjustment disorder with anxiety was ongoing. Vistagen was preparing a U.S. IND for PH10 and planned a small Phase 1 study before year-end 2022, with potential Phase 2B development in 2023. An exploratory Phase 1B study of AV-101 with probenecid was ongoing.
- Management stated that available cash was expected to fund planned operations for at least 12 months following issuance of the financial statements. The company expects ongoing losses and negative operating cash flows and will need substantial additional capital to advance programs and potentially commercialize products. It may pursue equity or debt financing, collaborations, grants, or warrant exercises; future funding is not assured and equity financing could dilute shareholders.
- Key risks include clinical failure or delays, dependence on external manufacturers and clinical providers, potential COVID-19-related supply or trial disruptions, competition, intellectual-property challenges, and financing needs. The filing also reported a Nasdaq closing share price of $0.17 on August 10, below the $1.00 minimum bid-price requirement.
- The company reported no legal proceedings and no off-balance-sheet arrangements. Management concluded disclosure controls were effective at quarter-end; it reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- The independent interim analysis of PALISADE-2 and the company’s subsequent decision on that trial and PH94B’s development path.
- Whether FDA discussions support a revised PH94B clinical strategy, particularly in light of PALISADE-1’s missed primary endpoint.
- Actual cash burn and runway after the program changes, and whether the stated minimum 12-month funding horizon remains valid.
- PH10 IND and Phase 1 timing, progress of the PH94B adjustment-disorder study, and results and next steps for AV-101 with probenecid.
- Future financing requirements and potential dilution, including use of the ATM program and outstanding warrants.